In 2021, it was approved as a once weekly injection for chronic weight management in adults and kids down to age 12 as Wegovy
New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs
In the STEP 1 trial, adults with overweight or obesity without diabetes who took semaglutide 2.4 mg lost an average of 14.9% of their body weight at 68 weeks
Global GLP-1 Receptor Agonist Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Semaglutide, Dulaglutide, Liraglutide, Exenatide), By Type (Victoza, Ozempic, Saxenda, Trulicity, Bydureon), By Application (Type 2 Diabetes, Obesity, and Others), By Route of Administration (Parenteral and Oral), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 2032 Industry: Healthcare Global GLP-1 Receptor Agonist Market Insights Forecasts to 2032 The Global GLP-1 Receptor Agonist Market Size was valued at USD 13.4 Billion in 2022
doi: 10.1021/acsptsci.2c00212